Loading...


*  Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes-a Dangerous Ally | touchENDOCRINOLOGY
There is a rising trend of overweight and obesity in individuals with type 1 diabetes (T1D). The prevalence of overweight and ... 2 This has been attributed to a general worldwide increase in prevalence of obesity and similar risk factors such as family ... in the 2-19 year age group in the Pediatric Diabetes Consortium and the SEARCH for Diabetes in Youth study.1, ... Sodium-glucose Co-transporter-2 Inhibitors in Type 1 Diabetes-a Dangerous Ally. Gagan Priya, Sanjay Kalra, Vishal Bhambri ...
  http://www.touchendocrinology.com/articles/sodium-glucose-co-transporter-2-inhibitors-type-1-diabetes-dangerous-ally
*  People With Type 1 Diabetes at Risk of Thyroid Disease - Drugs.com MedNews
may be as high as 30 percent in people with type 1 diabe ... People who have type 1 diabetes are more likely than others to ... Steglatro Steglatro (ertugliflozin) is a sodium-glucose co-transporter-2 (SGLT2) inhibitor to help improve glycemic... ... Home › News › Consumer News › People With Type 1 Diabetes at Risk of Thyroid Disease ... People who have type 1 diabetes have to replace the lost insulin, using shots of insulin or an insulin pump with a tube ...
  https://www.drugs.com/news/type-1-diabetes-risk-thyroid-43673.html
*  Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals
Meta-analysis explores safety and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with type 1 diabetes. ... ESRD in Type 1 Diabetes: What Has Changed? Although the risk of end-stage renal disease remains high for individuals with type ... Continuous Glucose Monitoring Systems (CGMS) are big news and many experts say they will revolutionize diabetes management. But ... Breastfeeding Reduces Risk of Developing Diabetes 30-year study shows effects of breastfeeding on diabetes incidence in women ...
  http://www.diabetesincontrol.com/?option=com_content&task=view&id=14245&Itemid=8
*  A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus - Full Text View -...
Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 ... Diabetes Mellitus. Diabetes Mellitus, Type 1. Glucose Metabolism Disorders. Metabolic Diseases. Endocrine System Diseases. ... The results will help determine doses of GSK189075 can be studied in the future in the type I diabetes mellitus population. ... Percent of Filtered Glucose in the Urine. [ Time Frame: Up to 24 hours post dose of each treatment period. ]. Filtered glucose ...
  https://clinicaltrials.gov/ct2/show/NCT00575159?cond=%22Diabetes+Mellitus%2C+Type+1%22&rank=5
*  Remogliflozin etabonate - Wikipedia
... a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes". Diabetes Care. ... Diabetes Obes Metab. 14: 15-22. doi:10.1111/j.1463-1326.2011.01462.x. PMID 21733056. Sykes, AP; O'Connor-Semmes, R; Dobbins, R ... and type 2 diabetes. Remogliflozin is being developed by Avolynt, Inc. Remogliflozin etabonate (RE) was shown to enhance ... Remogliflozin inhibits the sodium-glucose transport proteins (SGLT), which are responsible for glucose reabsorption in the ...
  https://en.wikipedia.org/wiki/Remogliflozin_etabonate
*  ADA: New Type 2 Drug May Work in Type 1 Diabetes | Medpage Today
An investigational agent for type 2 diabetes may also work as add-on therapy in type 1 disease, researchers reported here. ... He added that the mechanism of dapagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, would be beneficial in type ... American Diabetes Association. Source Reference: Henry RR, et al "Exploring the potential of dapagliflozin in type 1 diabetes: ... "We were able to show improvements in both fasting and postprandial glucose, a reduction in excursions of glucose, and a ...
  https://www.medpagetoday.com/meetingcoverage/ada/40091
*  A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin | BenthamScience
Current Diabetes Reviews. *Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors ... urinary glucose excretion.. Abstract:Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class of anti-diabetic ... A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin Author(s): Saad Hussain ... Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class of anti-diabetic medications. Canagliflozin was the first ...
  http://www.eurekaselect.com/136697
*  Diabetes Alliance to Feature 17 Presentations for Linagliptin and Investigational Compound Empagliflozin^ During the 49th...
Diabetes,(EASD),medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical ... It...Details of clinical presentations for empagliflozin are as follows:su...,Diabetes,Alliance,to,Feature,17,Presentations,for ... Empagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor being investigated for the reduction of blood glucose ... About Diabetes Approximately 25.8 million Americans6 and an estimated 371 million people worldwide have type 1 or type 2 ...
  http://www.bio-medicine.org/medicine-technology-1/Diabetes-Alliance-to-Feature-17-Presentations-for-Linagliptin-and-Investigational-Compound-Empagliflozin-5E-During-the-49th-Annual-Meeting-of-the-Euro-35682-1/
*  August 3, 2015
It's a sodium-glucose co-transporter 2 inhibitor. Big words for a little pill. This drug works to lower blood glucose levels by ... diabetes diabetic ketoacidosis eDKA euglycemic DKA invokana invokana and type 1 diabetes sglt2 inhibitor Type 1 diabetes ... When a Type 2's BG is high, they can have diabetic hyperglycemic hyperosmolar syndrome without ketones.) If they don't know ... That filtered glucose is then… excreted. (You pee it out.). It's also prescribed for people with Type 2 diabetes and "not ...
  https://www.theperfectd.com/2015/08/03/invoking-invokana-and-type-1-diabetes/
*  Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in...
American Diabetes Association. Standards of medical care in diabetes-2016. Diabetes Care. 2016;39(suppl 1):S1-108.Google ... Type 2 diabetes mellitus and hypertension: an update. Endocrinol Metab Clin N Am. 2014;43(1):103-22.View ArticleGoogle Scholar ... Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor approved to treat adults with T2DM [10]. SGLT2 inhibition ... Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci. ...
  https://cardiab.biomedcentral.com/articles/10.1186/s12933-017-0511-0
*  Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002) - Full Text View -...
A known hypersensitivity or intolerance to any sodium-glucose co-transporter 2 (SGLT2) inhibitor ... History of other specific types of diabetes (eg, genetic syndromes, secondary pancreatic diabetes, diabetes due to ... Diabetes Mellitus. Diabetes Mellitus, Type 2. Glucose Metabolism Disorders. Metabolic Diseases. Endocrine System Diseases. ... Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002). The safety and scientific validity of ...
  https://clinicaltrials.gov/show/NCT01999218
*  Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate...
A known hypersensitivity or intolerance to any sodium-glucose co-transporter 2 (SGLT2) or DPP-4 inhibitor ... History of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrine ... other sodium-glucose co-transporter 2 (SGLT2) inhibitors, alpha glucosidase inhibitors or meglitinides, bromocriptine (Cycloset ... Type 2 Diabetes Mellitus. Intervention ICMJE *Drug: Ertugliflozin 5 mg Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks ...
  https://clinicaltrials.gov/ct2/show/record/NCT02036515?term=VERTIS+SITA2&rank=1
*  Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis...
We aimed to assess the safety and efficiency of the novel sodium glucose co-transporter 2 (SGLT2) inhibitor in combinations ... with insulin for type 1 and type 2 diabetes mellitus (T1DM and T2DM). ... Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes: Systematic review and meta-analysis ... fasting plasma glucose (FPG) (MD −1.01 mmol/L, 95%CI [−1.98 to 0.04], P = .04), insulin dosage (MD −4.85 U/24 hours, 95%CI [− ...
  https://insights.ovid.com/pubmed?PMID=28538386
*  Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes | SpringerLink
Type 2 diabetes mellitus (T2DM) is a growing worldwide epidemic. Patients face lifelong therapy to control hyperglycemia and ... low-capacity glucose transporter sodium glucose cotransporter 1, SGLT1 (Figure 1A).29,30 However, while SGLT2 is predominantly ... Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-657.PubMedCrossRef ... Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2) reduces serum glucose in type 2 ...
  https://link.springer.com/article/10.1007%2Fs13300-010-0007-3
*  Home - ADA Daily News
American Diabetes Association - Read every article from every issue plus exclusive online-only content updated daily with the ... off-label use of sodium-glucose co-transporter 2 inhibitors continues to increase. An expert panel that includes Ele Ferrannini ... The ADA and the European Association for the Study of Diabetes (EASD) will release the first public draft of a new consensus ... Banting Medal recipient looks to liver, muscle for novel type 2 diabetes treatments. Posted By: ADA Daily ...
  https://www.adadaily.org/
*  Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program | Diabetes Care
Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to ... were reported to have autoimmune diabetes (latent autoimmune diabetes of adulthood [LADA] or type 1 diabetes) or to have tested ... Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499-508pmid ... Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med ...
  http://care.diabetesjournals.org/content/38/9/1680
*  Dapagliflozin (Forxiga) and canagliflozin (Invokana) sodium-glucose co-transporter-2 inhibitors for add-on therapy in type 2...
The new SGLT-2 inhibitors have been PBS listed as dual oral therapy in combination with either metformin or a sulfonylurea in ... Diabetes Care 2011;34:2015-22. [PubMed]. *Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 ... Sodium-glucose co-transporter-2 (SGLT2) inhibitors block glucose reabsortion in the kidneys, so efficacy is dependent on kidney ... SGLT2 is a low-affinity, high-capacity sodium-coupled glucose transporter located on the luminal side of the renal proximal ...
  https://www.nps.org.au/radar/articles/dapagliflozin-forxiga-and-canagliflozin-invokana-sodium-glucose-co-transporter-2-inhibitors-for-add-on-therapy-in-type-2-diabetes-mellitus
*  Diabetes Devices Market to Expand With a CAGR of 6.7% due to Growing Incidence of Diabetes, Observes TMR
According to TMR, the diabetes devices market was valued at US$37220.8 mn in 2016 and expected to attain a value of US$66,053.1 ... Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors, and Insulin; Disease Type - Type 1 Diabetes, Type 2 Diabetes, Gestational ... Product Type - Glucose Monitoring Devices (Self-monitoring Blood Glucose Meters, Blood Glucose Testing Strips, Lancets, and ... Based on the product type, the glucose meter is dominated to the global market for diabetes devices in 2016 by accounting the ...
  https://www.medindia.net/health-press-release/Diabetes-Devices-Market-to-Expand-With-a-CAGR-of-67-due-to-Growing-Incidence-of-Diabetes-Observes-TMR-393893-1.htm
*  Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2...
Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, ... Diabetes Mellitus, Type 2. *Hypertension. Intervention ICMJE *Drug: Canagliflozin One 100 mg or 300 mg over-encapsulated tablet ... Change From Baseline in Fasting Plasma Glucose (FPG) to Week 6 [ Time Frame: Baseline and Week 6 ]. The fasting plasma glucose ... patients with a diagnosis of type 2 diabetes mellitus. *patients with hypertension (seated office SBP of ,=130 mmHg and ,160 ...
  https://clinicaltrials.gov/ct2/show/record/NCT01939496?show_rss=Y&sel_rss=mod14
*  LX4211 Achieves Positive Results In Type 1 Diabetes Clinical Trial on NewsHub.org
LX4211 is an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) that is designed to ... lower blood glucose levels through two insulin-independent mechanisms of action. News on NewsHub.org ... Nasdaq: LXRX) announced today positive, top-line results in a Phase 2 clinical trial of LX4211 in type 1 diabetes, which ... LX4211 is an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) that is designed to ...
  http://www.newshub.org/m/lx4211-achieves-positive-results-type-1-diabetes-clinical-trial-633930.html
*  Combination drug for adults with type 2 diabetes mellitus - The Clinical Advisor
Glyxambi is adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment ... Pharmacologic class: Sodium-glucose co-transporter 2 inhibitor + dipeptidyl peptidase-4 inhibitor ... Pharmacology: Empagliflozin, a sodium-glucose co-transporter 2 inhibitor, reduces renal reabsorption of filtered glucose and ... Indication(s): Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment ...
  https://www.clinicaladvisor.com/drug-update/combination-drug-for-adults-with-type-2-diabetes-mellitus/article/435798/
*  Effect of Self-Monitoring of Blood Glucose in Patients With Type 2 Diabetes Mellitus Not Using Insulin
... is one of the important instruments in diabetes management. Most patients with type... ... clinicaltrials.gov Self-monitoring of blood glucose (SMBG) ... A glucoside-derived SODIUM-GLUCOSE TRANSPORTER 2 inhibitor that ... and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a ... Knowing where I am': self-monitoring of blood glucose in diabetes.. Although the prevalence of all types of chronic conditions ...
  https://www.bioportfolio.com/resources/trial/109612/Effect-of-Self-Monitoring-of-Blood-Glucose-in-Patients-With-Type-2.html
*  Type 2 Diabetes: The 'AIDS' of the 21st Century? - Drugs.com MedNews
The International Diabetes Federation (IDF) has called for urgent action to stem the growing epidemic of type 2 diabetes by ... Steglatro Steglatro (ertugliflozin) is a sodium-glucose co-transporter-2 (SGLT2) inhibitor to help improve glycemic... ... Diabetes Care 1998; 21: 1414-31.. *American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care ... Diabetes Atlas 2000. International Diabetes Federation.. *King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025. ...
  https://www.drugs.com/news/type-2-diabetes-aids-21st-century-1214.html
*  High interest in inhibitors of the novel target sodium-dependent glucose (co-) transporter (SGLT) for therapy of type 2...
... transporter (SGLT) for therapy of type 2 diabetes : Pharmaceutical feature , PharmiWeb.com ... High interest in inhibitors of the novel target sodium-dependent glucose (co-) ... High interest in inhibitors of the novel target sodium-dependent glucose (co-) transporter (SGLT) for therapy of type 2 ... diabetes. Posted on: 23 Jan 06. Summary. A plethora of SGLT inhibitors in the patent literature and seven compounds in early ...
  https://www.pharmiweb.com/features/feature.asp?row_id=722
*  Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants...
History of sensitivity to ertugliflozin or other Sodium-Glucose co-Transporter 2 (SGLT2) inhibitors ... For T2DM participants, history of type 1 diabetes mellitus or a history of ketoacidosis ... T2DM participants have a diagnosis of T2DM as per American Diabetes Association guidelines ... Urinary Glucose Excretion Over 24 Hours (UGE0-24hr) [ Time Frame: Up to 24 hours ] ...
  https://clinicaltrials.gov/ct2/show/record/NCT01948986